Drc  Congo Health authorities said on Monday that two experimental drugs being used in a clinical trial basis to control the spread of Ebola appear to be "Saving lives"

The drugs  SUPPOSEDLY developed from antibodies from THE survivors that had been infected with Ebola — shows evidenctly better" results in patients taking part in the trial, which is being conducted during the world's second-largest Ebola outbreak in the Democratic Republic of the Congo (DRC).

What are these drugs being tested andon trial?


  • US National Institutes of Health's 'mAb114'
  • Regeneron's REGN-EB3
  • Gilead Sciences' Remdesivir
  • Mapp Biopharmaceutical's ZMapp

The trials of the first Regeneron's REGN-EB3  and US National Institutes of Health's 'mAb114' drugs were considered successful: they clearly worked better, and the second — developed by US scientists — wasn't far behind. Both improved survival rates from Ebola more than the two other products being tested. ZMapp and Remdesivir have now been dropped, according to Anthony Fauci, one of the trial researchers.

Fauci, director of the US National Institute of Allergy and Infectious Diseases, said the results were "very good news" for the fight against Ebola.

Very Inspiring indeed

"What this means is that we do now have what look like [two] treatments for a disease for which not long ago we really had no approach at all."

In the study, fewer people died among those given the Regeneron drug or the NIH's — about 30% compared to half who received ZMapp. More striking, when patients sought care early — before too much virus was in their bloodstream - mortality was just 6% with the Regeneron drug and 11% with the NIH compound, compared to about 24% for ZMapp, Fauci said. 

The World Health Organization says the findings should encourage more people to seek care rapidly, even as further study continues.

Since the Ebola outbreak the Virus have since claimed over 1800 lives. This is very good development indeed.